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ABSTRACT 
A new method has been established for the simultaneous estimation of Telmisartan and Atorvastatin calcium by RP-HPLC method. The 
chromatographic conditions were successfully developed for the separation of Telmisartan and Atorvastatin calcium by using boston ODS C18 
column, flow rate was 1.0ml/min, mobile Phase consists of methanol:Acetonitrile:buffer in ratio of 35:25:40. Detection wave length was 
235nm.The instrument used was SHIMADZU HPLC auto sampler. The retention time of Atorvastatin calcium and Telmisartan was found to be 
2.350 and 3.490 minutes respectively. The analytical method was validated according to ICH guidelines (ICH Q2b). The correlation coefficient 
(r2) was found to be 0.997 and 0.999 for Telmisartan and Atorvastatin calcium respectively. % mean recovery was found to be 100.943% and 
100.576% for Telmisartan and Atorvastatin calcium respectively. %RSD for precision on replicate injection was 0.46 and 0.70 for Telmisartan 
and Atorvastatin calcium respectively. The validation study was found to be precise, robust, and repeatable.  
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INTRODUCTION 
Telmisartan 
Telmisartan is an orally active non peptide Angiotensin ІІ 
antagonist that acts on the AT1 receptor subtype. 
Telmisartan interferes with the binding of angiotensin II to 
the angiotensin II AT1-receptor by binding reversibly and 
selectively to the receptors in vascular smooth muscle and 
the adrenal gland. As angiotensin II is a vasoconstrictor, 
which also stimulates the synthesis and release of 
aldosterone, blockage of its effects results in decreases in 
systemic vascular resistance. Telmisartan does not inhibit 
the angiotensin converting enzyme, other hormone 
receptors, or ion channels1-3.  
 
Figure 1: Chemical Structure of Telmisartan 
 
Atorvastatin calcium 
Atorvastatin calcium (ATV), (βR,dR)-2-(4fluorophenyl)-β,d-
dihydroxy-5-(1-methylethyl)-3-phenyl4-[(phenylamino) 
carbonyl]-lH-pyrrole-1-heptanoic acid, calcium salt, is a 
synthetic cholesterol-lowering agent1. Atorvastatin calcium 
selectively and competitively inhibits the hepatic Hydroxy 
methyl glutaryl-coenyme A (HMG-CoA) reductase, the rate-
determining enzyme located in hepatic tissue that produces 
mevalonate, a small molecule used in the synthesis of 
cholesterol and other mevalonate derivatives. This lowers 
the amount of cholesterol produced which in turn lowers the 
total amount of LDL cholesterol.4-6 
 
Figure 2: Chemical Structure of Atorvastatin calcium 
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METHODS & MATERIALS 
Chemicals and reagents Analytically pure Telmisartan and 
Atorvastatin calcium were obtained as gift samples from Sun 
Pharmaceutical Pvt. Ltd., Baroda, India. AR grade 
acetonitrile, methanol, Triethylamine, Potassium Dihydrogen 
phosphate, Sodium Dihydrogen phosphate were obtained 
from E. Merck Ltd., Mumbai, India. Tablet formulation 
Telmisartan and Atorvastatin calcium tablets were 
purchased from local market.  
Method development of telmisartan and atorvastatin 
calcium by RP-HPLC7-12: 
The detection wavelength was selected by dissolving 
Telmisartan and Atorvastatin calcium in diluent to get 
concentration of the 10 g/ml. The resulting solution was 
scanned in U.V range from 200-400nm. The absorbance 
maximum was found to be 235nm. The chromatographic 
method development for the estimation of Telmisartan and 
Atorvastatin calcium were optimized by several trials for 
various parameters as different column, flow rate and mobile 
phase, finally the following chromatographic method was 
selected for the separation and quantification of Telmisartan 
and Atorvastatin calcium in API and pharmaceutical dosage 
form by RP-HPLC.  
Preparation of solutions for optimized conditions of 
method validation8-10: 
Buffer Preparation: 
1.3609 gm of Potassium di-hydrogen phosphate was added 
in sufficient water to produce 1000ml, pH adjusted to 4.5 
with orthophosphoric acid. 
Solvent mixture:  
Prepare mixture of methanol, acetonitrile and buffer in ratio 
of 35:25:40v/v respectively. 
Mobile phase:  
Prepare a filtered (0.45µ) and degassed mixture of methanol, 
acetonitrile and buffer preparation in ratio of 35:25:40v/v 
respectively. 
Chromatographic conditions:  
Parameter Condition 
Column Boston ODS C18 column 
Mobile phase methanol:Acetonitrile:buffer 
35:25:40 
Column Temperature 250C 
Wavelength 235nm 
Flow rate 1.0 ml/min 
Auto sampler 
temperature 
Ambient 
Injection volume 0.2ml 
Run time 8 minutes 
 
 
RESULTS AND DISCUSSION 
 
Figure 3: chromatogram 
S.NO Name RT(min)    Asymmetry Theoritical plates   Area Resolution 
     1    AC 2.350 1.370 2382 136.161    -- 
     2    TM 3.490 1.316 3284 1035.333 5.227 
 
Linearity:             
The linearity study was performed for the concentration of 
60ppm to 140ppm level. Each level was injected into 
chromatographic system the area of each level was used for 
calculation of correlation coefficient. The linearity study was 
performed and the correlation coefficient of Telmisartan and 
Atorvastatin calcium was found to be 0.999 and 0.997 
respectively (NMT 0.999). 
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                Figure 4:  Calibration curve of Telmisartan               Figure 5:  Calibration curve of Atorvastatin calcium 
Table 1: Results of linearity study 
S.No Linearity 
Level 
Concentration Area of 
Telmisartan 
Area of Atorvastatin 
calcium 
1 I 60ppm 635.316 86.613 
2 II 80ppm 804.182 105.914 
3 III 100ppm 928.411 122.129 
4 IV 120ppm 1101.576 142.812 
5 V 140ppm 1274.763 169.731 
Correlation coefficient 0.999 0.997 
 
Accuracy 
Accuracy of the method was determined by Recovery 
studies. To the formulation (pre analysed sample), the 
reference standards of the drugs were added at the level of 
80%, 100%, 120%. The recovery studies were carried out 
three times and the percentage recovery and percentage 
mean recovery were calculated for drug. 
 
Table 2: Results for accuracy of Telmisartan 
Recovery 
level 
                        Accuracy of telmisartan Average  
% Recovery Amount taken 
(mcg/ml) 
Area Average area Amount 
recovered 
(mcg/ml) 
%Recovery 
80% 64 1035.01  
1032.530 
 
81.16 
 
101.45 
 
 
 
 
 
100.943 % 
64 1026.185 
64 1036.395 
100% 80 1101.576  
1104.674 
 
 95.19 
 
99.15 80 1102.274 
80 1110.173 
120% 96 1328.71    
 1313.850 
 
  114.50 
 
102.23 96 1322.727 
96 1290.113 
 
Table 3: Results for accuracy of Atorvastatin calcium 
Recovery 
level 
                   Accuracy of Atorvastatin calcium Average  
% Recovery 
Amount taken 
(mcg/ml) 
Area Average 
area 
Amount recovered 
(mcg/ml) 
%Recovery 
80%  16 130.148  
133.703 
 
20.20 
 
100.99 
 
 
100.576  % 
 
 
 
16 135.519 
16 135.443 
100% 20 142.812  
144.957 
 
23.74 
 
98.91 20 143.275 
20 148.784 
120% 24 172.511  
169.660 
 
28.51 
 
101.83 24 167.307 
24 169.163 
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Precision: 
The precision study was performed for six injections of Telmisartan and Atorvastatin calcium. Each standard was injected into 
chromatographic system. The area of each standard injection was used for calculation of %RSD.  
Table 4: Method precision results for Telmisartan and Atorvastatin calcium 
S.NO. Telmisartan Atorvastatin   calcium 
Retention Time Area Retention Time Area 
   1 3.510 1015.834 2.363 126.473 
   2 3.500 1026.375 2.35 135.444 
   3 3.510 1023.904 2.36 133.190 
  4 3.513 1023.366 2.363 133.075 
  5 3.470 1041.225 2.32 135.357 
  6 3.503 1021.136 2.357 133.526 
 Average 3.501 1025.307 2.3522 132.844 
 SD 0.016 8.572 0.0165 3.296 
 %RSD 0.46 0.84 0.70 2.48 
 
Robustness: 
Chromatographic conditions variation:  
To demonstrate the robustness of the method, prepared solution as per test method are injected at different variable conditions 
like using different conditions like flow rate and wavelength. System suitability parameters were compared with that of method 
precision. 
Table 5: Robustness results for Telmisartan and Atorvastatin calcium 
 
Parameter 
Telmisartan    Atorvastatin calcium 
Retention 
time(min) 
Asymmetry Retention 
time(min) 
Asymmetry 
Flow Rate 
0.8 ml/min 
1.2 ml/min 
 
4.450 
2.830 
 
1.319 
1.273 
 
2.987 
1.900 
 
1.294 
1.292 
Wavelength 
233nm 
237nm 
 
3.490 
3.500 
 
1.316 
1.324 
 
2.347 
2.350 
 
1.286 
1.333 
 
Ruggedness: 
Ruggedness of the method was studied by determining the analyst to analyst variation by performing the Assay by two different 
analysts 
Table 6: Ruggedness results for Telmisartan and Atorvastatin calcium 
 
Parameter 
Telmisartan    Atorvastatin calcium 
Retention time(min) Asymmetry Retention time(min) Asymmetry 
Analyst 1 
Standard 
sample 
 
3.510 
3.500 
 
1.324 
1.277 
 
2.363 
2.350 
 
1.259 
1.346 
Analyst 2 
Standard 
sample 
 
3.510 
3.500 
 
1.263 
1.297 
 
2.360 
2.350 
 
1.296 
1.333 
 
Table 7: Results for system suitability of Telmisartan and Atorvastatin calcium 
Injecti
on 
Telmisartan Atorvastatin calcium 
RT Peak 
area 
Theoretical 
plates 
Asymmetry RT Peak 
area 
Theoretical 
plates 
Asymmetry 
1 3.510 1015.834  3482 1.324  2.363 126.473  2557  1.259 
2 3.500 1026.375  3463  1.297  2.350 135.444  2382  1.333 
3  3.510 1023.904  3482  1.263  2.360 133.190  2550  1.297 
4  3.513 1023.366  3329  1.289  2.363 133.075  2409  1.250 
5  3.470 1041.225  3403  1.324  2.320 135.357  2621  1.280 
6  3.503 1021.136  3310  1.263  2.357 133.526  2395  1.259 
Mean  3.501 1025.307   2.3522 132.844   
SD  0.016  8.572   0.016  3.296   
%RSD  0.70  2.48    0.70  2.48   
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